| Year |
Citation |
Score |
| 2023 |
Hehir MK, Conaway M, St Sauveur AB, Feb K, Kolb NA, Waheed W, McNeish BL, Tweedy N, Burns TM. Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU). Muscle & Nerve. PMID 37676119 DOI: 10.1002/mus.27966 |
0.655 |
|
| 2022 |
Hehir MK, Conaway M, Clark EM, Aronzon DB, Kolb N, Kolb A, Ruzhansky K, Sadjadi R, De Sousa EA, Burns TM. The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events. Plos One. 17: e0262109. PMID 35176061 DOI: 10.1371/journal.pone.0262109 |
0.64 |
|
| 2021 |
Nowak RJ, Coffey CS, Goldstein JM, Dimachkie MM, Benatar M, Kissel JT, Wolfe GI, Burns TM, Freimer ML, Nations S, Granit V, Smith AG, Richman DP, Ciafaloni E, Al-Lozi MT, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology. PMID 34857535 DOI: 10.1212/WNL.0000000000013121 |
0.536 |
|
| 2020 |
Barohn RJ, Gajewski B, Pasnoor M, Brown A, Herbelin LL, Kimminau KS, Mudaranthakam DP, Jawdat O, Dimachkie MM, Iyadurai S, Stino A, Kissel J, Pascuzzi R, Brannagan T, ... ... Burns T, et al. Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial. Jama Neurology. PMID 32809014 DOI: 10.1001/Jamaneurol.2020.2590 |
0.638 |
|
| 2019 |
Machado P, Barohn R, McDermott M, Blaetter T, Lloyd T, Shaibani A, Freimer M, Amato A, Ciafaloni E, Burns T, Mozaffar T, Gibson S, Wicklund M, Saperstein D, Levine T, et al. P.02Phase 2/3 study of Arimoclomol in sporadic inclusion body myositis: study design Neuromuscular Disorders. 29. DOI: 10.1016/J.Nmd.2019.06.031 |
0.505 |
|
| 2018 |
Clifford KM, Hobson-Webb LD, Benatar M, Burns TM, Barnett C, Silvestri NJ, Howard JF, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, et al. Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle & Nerve. PMID 30575980 DOI: 10.1002/Mus.26404 |
0.655 |
|
| 2018 |
Kolb N, Burns T. Clinical research in chemotherapy-induced peripheral neuropathy: How, what, and when. Neurology. PMID 30054436 DOI: 10.1212/Wnl.0000000000006091 |
0.354 |
|
| 2018 |
Gwathmey KG, Sadjadi R, Horton WB, Conaway MR, Barnett-Tapia C, Bril V, Russell JW, Shaibani A, Mauermann ML, Hehir MK, Kolb N, Guptill J, Hobson-Webb L, Gable K, Raja S, ... ... Burns TM, et al. Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRI. Neurology. PMID 29728528 DOI: 10.1212/Wnl.0000000000005643 |
0.619 |
|
| 2017 |
Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF, Howard D, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, ... ... Burns TM, et al. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology. PMID 28801338 DOI: 10.1212/Wnl.0000000000004341 |
0.643 |
|
| 2015 |
Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, et al. Editorial by concerned physicians: Unintended effect of the Orphan Drug Act on the potential cost of 3,4-diaminopyridine. Muscle & Nerve. PMID 26662952 DOI: 10.1002/Mus.25009 |
0.648 |
|
| 2015 |
Gwathmey KG, Conaway MR, Sadjadi R, Joshi A, Barnett C, Bril V, Ng E, David W, Gable K, Guptill JT, Hobson-Webb LD, Dineen J, Hehir M, Brannagan TH, Byun E, ... ... Burns TM, et al. Construction and validation of the chronic acquired polyneuropathy patient-reported index, "CAP-PRI:" a disease-specific, health-related quality of life instrument. Muscle & Nerve. PMID 26600438 DOI: 10.1002/Mus.24985 |
0.653 |
|
| 2015 |
Hobson-Webb LD, Hehir M, Crum B, Visser A, Sanders D, Burns TM. Can mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis. Muscle & Nerve. 52: 211-5. PMID 25906756 DOI: 10.1002/Mus.24694 |
0.655 |
|
| 2012 |
Burns T, Sadjadi R, Conaway M, Cutter G, Sanders D. Psychometric Evaluation of Quality of Life (QoL) and Disease Severity Outcome Measures in Myasthenia Gravis (MG) Using Rasch Analysis (P05.174) Neurology. 78: P05.174-P05.174. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P05.174 |
0.339 |
|
| 2010 |
Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle & Nerve. 41: 593-8. PMID 20405499 DOI: 10.1002/Mus.21640 |
0.671 |
|
| 2010 |
Pasnoor M, Wolfe GI, Nations S, Trivedi J, Barohn RJ, Herbelin L, McVey A, Dimachkie M, Kissel J, Walsh R, Amato A, Mozaffar T, Hungs M, Chui L, Goldstein J, ... ... Burns T, et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle & Nerve. 41: 370-4. PMID 19882635 DOI: 10.1002/Mus.21533 |
0.383 |
|
| Show low-probability matches. |